Cosmo Pharmaceuticals and Olympus America Inc. Establish Co-Promotion Agreement for Eleview™

Cosmo Pharmaceuticals and Olympus America Inc. Establish Co-Promotion Agreement for Eleview™

Injection Agent Lowers Risk and Increases Efficiency During Resection and Gastrointestinal Endoscopic Procedures

Dublin - October 3, 2017 - Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that it has entered into an exclusive co-promotion agreement for Eleview ™ in the U.S. with Olympus America Inc., a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses. The co-promotion of Eleview™, an FDA 510(k)-cleared, ready-to-use submucosal injection composition, that provides an immediate and long-lasting cushion for gastrointestinal endoscopic resections of polyps, adenomas, and other lesions, will begin immediately.

Eleview™ is appropriate for challenging polyps, regardless of size, location, or type and the immediate, long-lasting cushion can hold for up to 45 minutes. Developed by Cosmo, Eleview™ improves margin visibility and helps decrease the risk of gastrointestinal perforation and damage to the external muscular layer, which can lead to gastrointestinal perforation. Furthermore, it decreases the time needed to resect a lesion while reducing both reinjections required and piecemeal excisions, as compared to saline.

"We are very happy to connect forces with our colleagues at Olympus through this co-promotion agreement," said Alessandro Della Chà, Chief Executive Officer of Cosmo Pharmaceuticals. "Olympus is the number one player in U.S. endoscopy and this agreement will be a boost for the commercial success of Eleview™."

"This innovative injection agent is a complement to our EndoTherapy portfolio and will further assist physicians during endoscopic procedures and when performing gastrointestinal resections," said Kurt Heine, Group Vice President of the Endoscopy Division at Olympus America Inc. "Better visibility of lesions, along with increased efficiency, can bring us closer to our goal of improving quality of care, reducing healthcare costs and enhancing patient satisfaction."

Cosmo's San Diego-based marketing and sales subsidiary, Aries Pharmaceuticals Inc., and Olympus will work together to promote Eleview™ to end-user customers and will each sell Eleview™ through their existing distribution networks. This combined effort will leverage Olympus' established salesforce and distribution network to address the colonoscopy market of 15 million annual procedures in an efficient and cost-effective manner.

The Eleview™ agreement will be highlighted at the American College of Gastroenterology's (ACG) World Congress of Gastroenterology conference in Orlando, October 13-18.

About Cosmo Pharmaceuticals

Cosmo is a specialty pharmaceutical company that aims to become a global leader in the field of optimized therapies for selected Gastrointestinal Disorders and Endoscopic Procedures. The Company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as Ulcerative Colitis and Crohn's Disease, and Colon Infections. In addition, the Company has developed a medical device for polyp and adenoma excision and is has completed clinical trials of LuMeBlue™, a diagnostic drug for the detection of colon cancer as well as new chemical entities that are being developed by the associate company Cassiopea S.p.A. for the topical treatment of skin diseases. Cosmo's MMX® products that have reached the market are Lialda®/Mezavant®/Mesavancol®, a treatment for IBD that is licensed globally to Giuliani and Shire Limited and Uceris®, the first glucocorticosteroid indicated for the induction of remission in active, mild to moderate Ulcerative Colitis, licensed in US to Santarus/Salix/Valeant and in the Rest of the World to Ferring as Cortiment®. Cosmo's proprietary MMX® technology is at the core of the Company's product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. The technology is designed to deliver active ingredients in a targeted manner in the colon. For further information on Cosmo, please visit the Company's website: www.cosmopharma.com

About Olympus Medical Systems Group

Olympus Medical Systems Group, a division of global technology leader Olympus, develops solutions for healthcare professionals that help improve clinical outcomes, reduce overall costs and enhance quality of life for their patients. By enabling less invasive procedures, innovative diagnostic and therapeutic endoscopy, and early stage lung cancer evaluation and treatments, Olympus is transforming the future of healthcare. For more information visit Olympus at www.medical.olympusamerica.com.

Contact

John Manieri, Head of Investor Relations

Cosmo Pharmaceuticals N.V.

Tel: [phone]
[e-mail]

Mark Miller

Olympus Corporation of the Americas

Vice President, Corporate and Medical Communications

Tel: [phone]
[e-mail]

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.

This communication is not an offer of securities of any issuer. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirement of the US Securities Act of 1933.

This press release constitutes neither an offer to sell nor a solicitation to buy securities and it does not constitute a prospectus within the meaning of article 652a and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange or any similar document. The offer will be made solely by means of, and on the basis of, a securities prospectus to be published. An investment decision regarding the securities to be publicly offered should only be made on the basis of the securities prospectus.

This press release is made to and directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. Any person who is not a relevant person should not act or rely on this press release or any of its contents.

This press release does not constitute an "offer of securities to the public" within the meaning of Directive 2003/71/EC of the European Union (the "Prospectus Directive") of the securities referred to in it (the "Securities") in any member state of the European Economic Area (the "EEA"). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.

Press release (PDF)

Provider		Channel		Contact
Tensid EQS Ltd., Switzerland www.tensid.ch		newsbox.ch www.newsbox.ch		Provider/Channel related enquiries [e-mail] [phone]